Vaxneuvance NDC 0006-4329

NDC codes

FDA NDC Directory

Product NDC (as listed)0006-4329Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00006-4329Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0006-4329-02	00006432902	1 SYRINGE, GLASS in 1 CARTON (0006-4329-02) / .5 mL in 1 SYRINGE, GLASS (0006-4329-01)Marketed from Jul 16, 2021
0006-4329-03	00006432903	10 SYRINGE, GLASS in 1 CARTON (0006-4329-03) / .5 mL in 1 SYRINGE, GLASS (0006-4329-01)Marketed from Jul 16, 2021

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Vaxneuvance
Generic name (nonproprietary): pneumococcal 15-valent conjugate vaccine crm197 protein adsorbed
Active ingredients: Streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen — 2 ug/.5mLStreptococcus pneumoniae type 3 capsular polysaccharide diphtheria crm197 protein conjugate antigen — 2 ug/.5mLStreptococcus pneumoniae type 4 capsular polysaccharide diphtheria crm197 protein conjugate antigen — 2 ug/.5mLStreptococcus pneumoniae type 5 capsular polysaccharide diphtheria crm197 protein conjugate antigen — 2 ug/.5mLStreptococcus pneumoniae type 6a capsular polysaccharide diphtheria crm197 protein conjugate antigen — 2 ug/.5mLStreptococcus pneumoniae type 6b capsular polysaccharide diphtheria crm197 protein conjugate antigen — 4 ug/.5mLStreptococcus pneumoniae type 7f capsular polysaccharide diphtheria crm197 protein conjugate antigen — 2 ug/.5mLStreptococcus pneumoniae type 9v capsular polysaccharide diphtheria crm197 protein conjugate antigen — 2 ug/.5mLStreptococcus pneumoniae type 14 capsular polysaccharide diphtheria crm197 protein conjugate antigen — 2 ug/.5mLStreptococcus pneumoniae type 18c capsular polysaccharide diphtheria crm197 protein conjugate antigen — 2 ug/.5mLStreptococcus pneumoniae type 19a capsular polysaccharide diphtheria crm197 protein conjugate antigen — 2 ug/.5mLStreptococcus pneumoniae type 19f capsular polysaccharide diphtheria crm197 protein conjugate antigen — 2 ug/.5mLStreptococcus pneumoniae type 22f capsular polysaccharide diphtheria crm197 protein conjugate antigen — 2 ug/.5mLStreptococcus pneumoniae type 23f capsular polysaccharide diphtheria crm197 protein conjugate antigen — 2 ug/.5mLStreptococcus pneumoniae type 33f capsular polysaccharide diphtheria crm197 protein conjugate antigen — 2 ug/.5mLCorynebacterium diphtheriae crm197 protein — 30 ug/.5mL
Dosage form: Injection, Suspension
Route: Intramuscular
Labeler: Merck Sharp & Dohme LLC
Product type: Vaccine
Marketing category: BLA — Biologics License ApplicationApplication BLA 125741
Marketing start: Jul 16, 2021
Listing expires: Dec 31, 2027
Other FDA classes: Actively Acquired Immunity (Physiologic effect)Actively Acquired Immunity (Physiologic effect)Actively Acquired Immunity (Physiologic effect)Actively Acquired Immunity (Physiologic effect)Actively Acquired Immunity (Physiologic effect)Actively Acquired Immunity (Physiologic effect)Actively Acquired Immunity (Physiologic effect)Actively Acquired Immunity (Physiologic effect)Actively Acquired Immunity (Physiologic effect)Actively Acquired Immunity (Physiologic effect)Actively Acquired Immunity (Physiologic effect)Actively Acquired Immunity (Physiologic effect)Actively Acquired Immunity (Physiologic effect)Pneumococcal Vaccines (Chemical structure)Pneumococcal Vaccines (Chemical structure)Pneumococcal Vaccines (Chemical structure)Pneumococcal Vaccines (Chemical structure)Pneumococcal Vaccines (Chemical structure)Pneumococcal Vaccines (Chemical structure)Pneumococcal Vaccines (Chemical structure)Pneumococcal Vaccines (Chemical structure)Pneumococcal Vaccines (Chemical structure)Pneumococcal Vaccines (Chemical structure)Pneumococcal Vaccines (Chemical structure)Pneumococcal Vaccines (Chemical structure)Pneumococcal Vaccines (Chemical structure)Conjugate (Chemical structure)Inactivated (Chemical structure)Inactivated (Chemical structure)Inactivated (Chemical structure)Inactivated (Chemical structure)Inactivated (Chemical structure)Inactivated (Chemical structure)Inactivated (Chemical structure)Inactivated (Chemical structure)Inactivated (Chemical structure)Inactivated (Chemical structure)Inactivated (Chemical structure)Inactivated (Chemical structure)
Identifiers: Product ID 0006-4329_15e0adcc-a482-4cc5-a25f-505ed47aa15dSPL ID 15e0adcc-a482-4cc5-a25f-505ed47aa15d
Pharmacologic class: Inactivated Pneumococcal Vaccine

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Immunization administration (CPT 90460–90474)

Giving a vaccine is reported separately from the vaccine product code, with an immunization administration code. Which code applies depends on the patient's age, the route and whether counselling was provided.

How CPT relates to drug billing

NDC on a medical claim

N400006432902 followed by a unit qualifier and the quantity

Package 00006-4329-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

The FDA listing for this product does not reference a label (SPL) set.